Fatty Liver to NASH: How Fat Turns Into Liver Scarring

Normal liver lipid handling — and the first hit

The liver is the body's central lipid-trafficking hub. Hepatocytes constantly take up free fatty acids (FFAs) from three sources: the plasma FFA pool released by adipose lipolysis (≈60% of liver fat in NAFLD), de novo lipogenesis (DNL) — building new fat from carbohydrate, ≈25% — and dietary chylomicron remnants (≈15%). These FFAs are normally either β-oxidized in mitochondria for energy or esterified into triglyceride and safely exported as very-low-density lipoprotein (VLDL).

Steatosis arises when input exceeds disposal. The master driver is insulin resistance. In insulin-resistant adipose tissue, insulin fails to suppress hormone-sensitive lipase, so lipolysis runs unchecked and floods the liver with FFAs. Simultaneously, hyperinsulinemia paradoxically stimulates DNL through the transcription factors SREBP-1c and ChREBP — the liver stays "insulin-sensitive" for lipogenesis while "insulin-resistant" for glucose. The result is triglyceride accumulation once liver fat exceeds 5% of hepatocytes (or 5.5% by MRI proton-density fat fraction). Importantly, stored triglyceride itself is relatively inert and protective — it is a buffer. Disease begins when that buffer is overwhelmed.

The lipotoxic 'second hit' — why fat becomes inflammation

The old "two-hit hypothesis" (fat, then oxidative stress) has been replaced by a multiple-parallel-hit model, but the central event is lipotoxicity. When triglyceride storage saturates, FFAs are shunted into toxic lipid species — diacylglycerols, ceramides, lysophosphatidylcholine, and free cholesterol. These are the villains, not the neutral triglyceride you see on ultrasound.

The causal chain to steatohepatitis:

1. Mitochondrial overload. Excess FFAs drive β-oxidation until mitochondria become dysfunctional, leaking reactive oxygen species (ROS) and causing lipid peroxidation.
2. ER stress. Lipid excess triggers the unfolded protein response, activating JNK signaling and pro-apoptotic pathways.
3. Hepatocyte injury. ROS and toxic lipids cause ballooning degeneration — swollen, rounded hepatocytes with rarefied cytoplasm — the histologic hallmark of NASH, plus apoptosis and necrosis.
4. Innate immune activation. Dying hepatocytes release damage-associated molecular patterns (DAMPs); gut-derived lipopolysaccharide (via a leaky gut) hits TLR4 on Kupffer cells (resident macrophages), which release TNF-α, IL-1β and IL-6.
5. Fibrogenesis. These signals plus TGF-β activate hepatic stellate cells, which transdifferentiate into myofibroblasts and deposit type I collagen.

This is the transition from bland steatosis (NAFL) to steatohepatitis (NASH): fat + ballooning + lobular inflammation. Only once injury and inflammation are present does meaningful fibrosis begin.

From inflammation to scar — the fibrosis staircase

Fibrosis in NASH follows a characteristic geography. Because injury centers on zone 3 (perivenular, most hypoxic and metabolically active region), collagen is first laid down in a pericellular, 'chicken-wire' pattern around individual hepatocytes and sinusoids — distinct from the portal-based fibrosis of viral hepatitis. Staging uses the NASH CRN fibrosis scale:

• F0 — no fibrosis
• F1 — perisinusoidal or periportal fibrosis (one compartment)
• F2 — perisinusoidal and periportal fibrosis (both compartments; "significant fibrosis")
• F3 — bridging fibrosis ("advanced fibrosis")
• F4 — cirrhosis

The clinical bottom line, established by landmark natural-history studies, is decisive: fibrosis stage — not the degree of steatosis or inflammation — is the strongest independent predictor of liver-related and all-cause mortality. On average, fibrosis advances about one stage every 7 years in NASH (roughly twice as slow, ≈1 stage per 14 years, in simple steatosis), but ≈20% are "rapid progressors." Once cirrhosis (F4) develops, the scarred, nodular liver can no longer regenerate normally, portal pressure rises, and the disease becomes potentially life-threatening.

Who gets it, and how it presents clinically

Epidemiology. NAFLD/MASLD affects ≈25-30% of the global adult population and is climbing with the obesity and type 2 diabetes epidemics. NASH is present in roughly 20-25% of those with NAFLD (≈5% of all adults). Prevalence approaches 60-70% in type 2 diabetes and >90% in morbid obesity. It is the leading cause of liver transplantation in women and the fastest-growing indication overall in the US, and an increasingly common cause of hepatocellular carcinoma.

Presentation. The overwhelming majority are asymptomatic — this is a silent disease. It is usually discovered incidentally through mildly elevated transaminases (often ALT > AST early — the opposite of alcoholic liver disease, where AST:ALT typically >2) or a "bright liver" on abdominal ultrasound done for another reason. When symptoms occur they are nonspecific: fatigue and dull right-upper-quadrant discomfort from hepatic capsular stretch. Hepatomegaly may be palpable. Look for the metabolic company it keeps: central obesity, acanthosis nigricans, hypertension, dyslipidemia. Signs of chronic liver disease — spider naevi, palmar erythema, gynecomastia, splenomegaly, ascites — appear only once cirrhosis is established. A crucial teaching point: transaminases can be entirely normal even with advanced fibrosis, so normal ALT never excludes NASH.

Diagnosis: excluding alcohol, then staging fibrosis

Diagnosis is one of exclusion plus confirmation. You must document hepatic steatosis (imaging or histology) AND exclude significant alcohol intake (the threshold is roughly <20 g/day for women, <30 g/day for men) and other causes — viral hepatitis, drugs, Wilson disease, hemochromatosis, autoimmune hepatitis. The 2023 MASLD nomenclature reframes this positively: steatosis plus at least one cardiometabolic risk factor (overweight, dysglycemia, hypertension, or dyslipidemia).

Staging fibrosis is the priority, and non-invasive tools have largely replaced routine biopsy:

• FIB-4 index — FIB-4 = (age × AST) ÷ (platelets × √ALT). <1.3 rules out advanced fibrosis (high negative predictive value); >2.67 suggests advanced fibrosis. The recommended first-line screen.
• Vibration-controlled transient elastography (FibroScan) — liver stiffness <8 kPa makes advanced fibrosis unlikely; >12-15 kPa suggests F3-F4.
• Enhanced Liver Fibrosis (ELF) test and MR elastography (most accurate imaging modality).
• Liver biopsy remains the gold standard and the only way to definitively distinguish NASH from bland steatosis and to grade activity (NAS score); reserved for diagnostic uncertainty or trials.

Natural history, complications, and why treatment works

Natural history if untreated. Simple steatosis is largely benign for the liver (though these patients still die more of cardiovascular disease than of liver disease — the leading cause of death across all NAFLD). NASH is the dangerous phenotype: ≈10-20% progress to cirrhosis over 10-20 years, with attendant risks of variceal hemorrhage, ascites, hepatic encephalopathy, and hepatocellular carcinoma — which in NASH can arise even before cirrhosis, an important and under-appreciated point.

Management targets the mechanism. The most effective therapy is weight loss, and the dose-response is precise: ≥5% body weight reduces steatosis, ≥7-10% resolves steatohepatitis and can regress fibrosis by reducing the FFA flux and lipotoxic load that started the cascade. Optimizing the metabolic drivers matters: pioglitazone (a PPARγ agonist that improves adipose insulin sensitivity), GLP-1 receptor agonists (semaglutide — weight loss plus direct metabolic benefit), and vitamin E 800 IU/day (an antioxidant countering the ROS step) in selected non-diabetics. In 2024, resmetirom, a liver-directed thyroid hormone receptor-β agonist that upregulates hepatic fat oxidation, became the first FDA-approved drug specifically for NASH with F2-F3 fibrosis. Because cardiovascular disease is the top killer, aggressive lipid and blood-pressure control is essential — treating a statin-eligible NAFLD patient with a statin is safe and recommended, dispelling a common myth that mildly raised transaminases forbid statins.

Simple steatosis (NAFL) vs steatohepatitis (NASH/MASH): the histologic and prognostic distinction that matters

Feature	Simple steatosis (NAFL)	Steatohepatitis (NASH/MASH)
Histology	Fat only (>5% hepatocytes)	Fat + ballooning + lobular inflammation ± Mallory-Denk bodies
Hepatocyte injury	Absent	Present (ballooning degeneration, apoptosis)
Fibrosis risk	Low, slow	Higher — progresses ≈1 stage per 7 years
Cirrhosis risk	Very low	≈10-20% over 10-20 years
Reversibility	Highly reversible with weight loss	Reversible early; fibrosis harder to reverse
Prognosis driver	Cardiovascular disease	Fibrosis stage → liver-related mortality